Initial public offerings scheduled to debut next week
March 12, 2021
FacebookTwitterEmail
NEW YORK (AP) The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
Week of March 15
Duckhorn Portfolio (The) - 20 million shares, priced $14-$16, managed by JP Morgan/Credit Suisse. Proposed NYSE symbol NAPA. Business: Produces and distributes luxury wine in North America.
Gain Therapeutics - Bethesda, Md., 3.6 million shares, priced $10-$12, managed by BTIG/Oppenheimer & Co. Proposed Nasdaq symbol GANX. Business: Preclinical biotech developing small molecule therapies for lysosomal storage.
Jowell Global - Shanghai, China, 3.7 million shares, priced at $7, managed by Network 1 Financial Securities. Proposed Nasdaq symbol JWEL. Business: Operates an e-commerce platform for cosmetics and health products in China.
(0)
BTIG Limited announced today that Kevin Edwards, Sean O Brien and Roxanne George have joined the firm s Fixed Income Credit division. Mr. Edwards joins BTIG as a Managing Director, focused on European financials and investment grade credit sales, while Mr. O Brien joins as a Director, concentrated on convertible sales trading. Ms. George joins the firm as a Vice President within Operations, where she will help lead BTIG s European middle office loan operations. In their new roles with the firm, they will be based in BTIG s London office. We are thrilled to have Kevin, Sean and Roxanne join our team and represent the firm in London, commented
(1)
BTIG Limited announced today that Ryan O Hagan has joined the firm s Institutional Equities division. Mr. O Hagan joins BTIG as a Managing Director and Equity Sales Trader focused on the European markets. In his new role with the firm, he will be based in BTIG s London office.
Mr. O Hagan has nearly 15 years of institutional equity sales trading experience. Prior to BTIG, he was a Managing Director within European and Emerging Markets at Morgan Stanley in London, where he specialized in equity products. Mr. O Hagan spent his entire career thus far with the firm, where he held several roles within the Institutional Equities division.
FT. MYERS, FL / ACCESSWIRE / February 16, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced